Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke
| Autor: | Dongdong Guo, Yansen Cui, Yanxue Gong, Shirui Zhang, Xiaolin Shao, Guangjian Zhao, Li-Quan Wang, Ziran Wang, Qinghua Zhang, Fan-zhen Lin, Dai-Qun Yang, Zhongrong Cheng, Hongyan Lei |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Stroke recurrence medicine.medical_treatment 030204 cardiovascular system & hematology Brain Ischemia 03 medical and health sciences 0302 clinical medicine Modified Rankin Scale medicine Humans Thrombolytic Therapy cardiovascular diseases Recombinant tissue plasminogen activator Aged Retrospective Studies Aspirin business.industry Dual Anti-Platelet Therapy Significant difference Thrombolysis Middle Aged Prognosis Clopidogrel Stroke Treatment Outcome Neurology Tissue Plasminogen Activator Anesthesia Ischemic stroke Administration Intravenous Female Neurology (clinical) business Platelet Aggregation Inhibitors 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | European Neurology. 82:93-98 |
| ISSN: | 1421-9913 0014-3022 |
| DOI: | 10.1159/000505241 |
| Popis: | Objective: To verify the efficacy and safety of dual antiplatelet therapy after intravenous thrombolysis for acute minor ischemic stroke (AMIS). Methods: AMIS patients who received recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis from January to October 2018 were retrospectively analyzed and divided into the aspirin (ASP) and ASP + clopidogrel (ASP-CLO) groups based on the type of antiplatelet therapy to compare the rates of good clinical outcome, symptomatic intracranial hemorrhage (SICH) after thrombolysis, and mortality in 90 days. Results: A total of 207 patients were included (group ASP, 105 patients; group ASP-CLO, 102 patients). There was no significant difference in the baseline clinical data between the 2 groups. The 90-day modified Rankin scale scores (66.7 vs. 82.4%, p = 0.009) showed a statistically significant difference, but SICH (1.0 vs. 1.0%, p = 0.917) and 90-day mortality (1.9 vs. 1.0%, p = 0.585) showed no significant difference between the 2 groups. Conclusions: Short-term (21 days) dual antiplatelet therapy after rt-PA intravenous thrombolysis for AMIS can improve the prognosis, reduce the risk of stroke recurrence, without increasing the risk of bleeding and mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|